Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05533736
Other study ID # 201875
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2020
Est. completion date December 1, 2021

Study information

Verified date September 2022
Source Centro Internacional de Entrenamiento e Investigaciones Médicas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An effectiveness-implementation sequential explanatory hybrid design type 2 was performed in two rural communities of Colombia. A quasi-experimental study with historical control (standard of care) was designed to estimate the effectiveness of community-based intervention using the Guaral+ST mobile application (app). Three implementation outcomes were evaluated: acceptability and usability by qualitative methods, and fidelity by quantitative methods


Description:

An effectiveness-implementation sequential explanatory hybrid design type 2 using mixed methods was performed in 2020 and 2021 in two study sites: Pueblo Rico, Risaralda, and Rovira, Tolima. A quasi-experimental study with historical control (standard of care) was designed to evaluate the effectiveness of the community-based intervention supported by mHealth, in terms of monitoring of treatment of patients with cutaneous leishmaniasis. The effectiveness indicators i. number of follow-up contacts, ii. Adherence to treatment, iii. adverse drug reactions, and iv. the therapeutic response were compared between the intervention and control groups. After the effectiveness evaluation was completed, three outcomes were assessed to inform the implementation of the community-based use of the app: acceptability, usability, and fidelity.


Recruitment information / eligibility

Status Completed
Enrollment 105
Est. completion date December 1, 2021
Est. primary completion date September 1, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Patients followed by CHL with the app (effectiveness evaluation): - Diagnosis confirmed by microscopy of tissue smear or culture - Any age and gender - Medical prescription for antileishmanial treatment - Approved and signed informed consent - Availability of CHL to monitor treatment of the patients in the community Inclusion Criteria patients who received the standard of care (effectiveness evaluation): - Clinical records of patients with confirmed CL at most two years prior to the start of this study - Any age and gender - Received antileishmanial treatment based on national guidelines Inclusion criteria for participants of implementation evaluation (Community Health Leaders) - Residents of the rural areas of study sites - Voluntary participation in the monitoring of patients using the mobile app

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis
Community Health leaders follow patients using the Guaral+ST app at final of treatment, and on days 90 and 180 after initiating the treatment.

Locations

Country Name City State
Colombia Corporación Centro Internacional de entrenamiento e Investigaciónes Médicas Cali Valle

Sponsors (2)

Lead Sponsor Collaborator
Centro Internacional de Entrenamiento e Investigaciones Médicas Universidad Icesi

Country where clinical trial is conducted

Colombia, 

References & Publications (7)

Agarwal S, Perry HB, Long LA, Labrique AB. Evidence on feasibility and effective use of mHealth strategies by frontline health workers in developing countries: systematic review. Trop Med Int Health. 2015 Aug;20(8):1003-14. doi: 10.1111/tmi.12525. Epub 2015 May 14. Review. — View Citation

Carrion C, Robles N, Sola-Morales O, Aymerich M, Ruiz Postigo JA. Mobile Health Strategies to Tackle Skin Neglected Tropical Diseases With Recommendations From Innovative Experiences: Systematic Review. JMIR Mhealth Uhealth. 2020 Dec 31;8(12):e22478. doi: 10.2196/22478. — View Citation

Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812. — View Citation

Mieras LF, Taal AT, Post EB, Ndeve AGZ, van Hees CLM. The Development of a Mobile Application to Support Peripheral Health Workers to Diagnose and Treat People with Skin Diseases in Resource-Poor Settings. Trop Med Infect Dis. 2018 Sep 15;3(3). pii: E102. doi: 10.3390/tropicalmed3030102. — View Citation

Navarro A, Rubiano L, Arango JD, Rojas CA, Alexander N, Saravia NG, Aronoff-Spencer E. Developing mobile health applications for neglected tropical disease research. PLoS Negl Trop Dis. 2018 Nov 1;12(11):e0006791. doi: 10.1371/journal.pntd.0006791. eCollection 2018 Nov. Review. — View Citation

Olliaro P, Grogl M, Boni M, Carvalho EM, Chebli H, Cisse M, Diro E, Fernandes Cota G, Erber AC, Gadisa E, Handjani F, Khamesipour A, Llanos-Cuentas A, López Carvajal L, Grout L, Lmimouni BE, Mokni M, Nahzat MS, Ben Salah A, Ozbel Y, Pascale JM, Rizzo Molina N, Rode J, Romero G, Ruiz-Postigo JA, Gore Saravia N, Soto J, Uzun S, Mashayekhi V, Vélez ID, Vogt F, Zerpa O, Arana B. Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation. PLoS Negl Trop Dis. 2018 Jan 12;12(1):e0006141. doi: 10.1371/journal.pntd.0006141. eCollection 2018 Jan. — View Citation

Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011 Mar;38(2):65-76. doi: 10.1007/s10488-010-0319-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The effectiveness of community-based intervention using the Guaral+ST mobile application was evaluated by four outcomes: i. The number of follow-ups The number of follow-up contacts between patients and health system or community health workers. 6 months
Primary ii. Percent adherence to treatment Relation between the number of doses administrated and the number of doses formulated by the physicians x 100. 6 months
Primary iii. Adverse drug reactions Frequency of adverse drug reactions: number of adverse drug reactions 6 months
Primary iv. Therapeutic response Cure: Completely re-epithelialised lesions on days 90 -180 after initiation of treatment
Failure: >50% increase in ulcer size from baseline at any time during evaluation or incomplete re-epithelialised on days 90-180
6 months
Secondary Implementation of the community-based strategy to follow patients with cutaneous Leishmaniasis was evaluated by three outcomes. i. Acceptability It refers to the perception among implementation stakeholders that the app is appealing, suitable, or satisfactory by a qualitative evaluation at three levels: community health leaders, health workers, and, and patients. 6 months
Secondary ii. Usability Refers to the degree to which the app can be used by community health leaders and health workers to achieve quantified objectives of effectiveness, efficiency, and satisfaction. It was evaluated using qualitatively at two levels: community health leaders and health workers. 6 months
Secondary iii. Fidelity It refers to the compliance (percentage) with the implementation strategy as described in the protocol. It was measured at two levels: Community Health Leaders and physicians. 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06011343 - Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis Phase 2/Phase 3
Completed NCT06449040 - Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly Phase 1/Phase 2
Completed NCT06000514 - Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. Phase 1/Phase 2
Completed NCT03829917 - Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Phase 2/Phase 3